The relationship between clinicopathological variables, systemic inflammation, and CT-derived body composition with survival in patients with advanced non-small cell lung cancer receiving nivolumab as a second-line treatment.
Randa SaeedJosh McGovernHugo BenchRoss D DolanDonald C McMillanAlmudena CascalesPublished in: Cancer medicine (2023)
In patients with advanced NSCLC receiving Nivolumab as a second-line therapy, ECOG-PS and hypoalbuminemia were strongly associated with survival. Systemic inflammation and hypoalbuminemia measurements may enhance the ECOG-PS stratification of expected outcomes.
Keyphrases
- advanced non small cell lung cancer
- body composition
- epidermal growth factor receptor
- resistance training
- bone mineral density
- free survival
- small cell lung cancer
- computed tomography
- image quality
- stem cells
- dual energy
- magnetic resonance imaging
- metabolic syndrome
- mesenchymal stem cells
- replacement therapy
- bone marrow
- skeletal muscle
- insulin resistance
- high intensity
- brain metastases